Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-19-Influenza Combination vaccine
- Development stage
- Phase 4
- Lead developer
- Novavax
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The COVID-19-Influenza Combination (CIC) vaccine is an investigational protein-based combination vaccine developed by Novavax. It combines the company's recombinant protein-based COVID-19 vaccine (NVX-CoV2373) with its quadrivalent nanoparticle influenza vaccine candidate into a single formulation. The vaccine utilizes Novavax's proprietary recombinant nanoparticle technology to produce hemagglutinin (HA) antigens for four influenza strains and the spike (S) protein antigen for SARS-CoV-2. It is formulated with the patented saponin-based Matrix-M adjuvant to enhance the immune response. Designed for intramuscular administration and stored at standard refrigeration temperatures (2-8°C), the vaccine aims to provide simultaneous protection against both seasonal influenza and COVID-19.
- Other names
- Novavax COVID-19-Influenza Combination vaccineICC vaccine-Novavax-COVID-19-Influenza
02
Targets
SARS-CoV-2 spikeHA (Hemagglutinin)
Beyond the preview
Go deeper on COVID-19-Influenza Combination vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID-19-Influenza Combination vaccine.